Compass Therapeutics Inc. (CMPX): Price and Financial Metrics
CMPX Price/Volume Stats
| Current price | $1.97 | 52-week high | $5.65 |
| Prev. close | $1.99 | 52-week low | $1.83 |
| Day low | $1.97 | Volume | 820 |
| Day high | $2.00 | Avg. volume | 412,366 |
| 50-day MA | $2.36 | Dividend yield | N/A |
| 200-day MA | $3.29 | Market Cap | 251.09M |
CMPX Stock Price Chart Interactive Chart >
Compass Therapeutics Inc. (CMPX) Company Bio
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development. The company was founded by Thomas J. Schuetz on March 20, 2018 and is headquartered in Boston, MA.
Latest CMPX News From Around the Web
Below are the latest news stories about COMPASS THERAPEUTICS INC that investors may wish to consider to help them evaluate CMPX as an investment opportunity.
Compass Therapeutics to Participate in Upcoming Investor EventsBOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023. Details are as follows: Citi’s 18th Annual BioPharma Conference Location: Boston, MAFormat: 1x1 MeetingsDate: Thursday, September 7 H.C. Wainwright 25 |
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateContinuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023Opened 20 clinical sites and continues to enroll patients in a U.S. Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024Completed enrollment of the dose-escalation portion of the Pha |
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® IndexesBOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023. Membership in the US all-cap Russell 3000® Index, which remains in place for |
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdateInitiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumE |
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQBOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the H.C. Wainwright BioConnect Investor Conference in New York City on Tuesday, May 2, 2023. Fireside Chat details:Date: Tuesday, May 2Time: 10 AM ETWebcast: https://journey.ct.events/view/059d01ae-0fdd-4419-8329-ac |
CMPX Price Returns
| 1-mo | -18.93% |
| 3-mo | -38.05% |
| 6-mo | -39.76% |
| 1-year | -11.26% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -60.83% |
| 2022 | 58.68% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...